Cancer treatment in Sweden - Costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs

Acta Oncologica

Volumn 37, Issue 5, 1998, Pages 447-453

  Ragnarson Tennvall, Gunnel ^a   Karlsson, Göran ^b  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; GEMCITABINE; GONADORELIN DERIVATIVE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 1 ANTAGONIST;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; HEALTH ECONOMICS; HODGKIN DISEASE; HOSPITAL PATIENT; HUMAN; LEUKEMIA; MELANOMA; MENINGIOMA; OUTPATIENT CARE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SWEDEN; TESTIS CANCER;

EID: 14444283398     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430395     Document Type: Article

References (32)

1. Stenbeck M, Rosén M, Holm L-E. Cancer survival in Sweden during three decades. 1961 1991. Acta Oncol 1995; 34: 881-891.
2. The National Board of Health and Welfare [Socialstyrelsen]. Cancer Incidence in Sweden 1994. Stockholm: Centre for Epidemiology, 1997.
3. The National Board of Health and Welfare [Socialstyrelsen]. Causes of death 1995 [Dödsorsaker 1995]. Stockholm: Centre for Epidemiology, 1997.
4. Jacobson L, Lindgren B. What are the costs for diseases? Health care costs and productivity losses distributed by disease group in 1980 and 1991 [Vad kostar sjukdomarna? Sjukvårdskostnader och produktionsbortfall fördelat på sjukdomsgrupper 1980 och 1991]. Stockholm: The National Board of Health and Welfare [Socialstyrelsen], 1996. In Swedish.
5. LINFO. Läkemedelsinformation AB. FASS 1996. Pharmaceuticals in Sweden [Läkemedel i Sverige]. Stockholm: LINFO, 1996. In Swedish.
6. The National Corporation of Swedish Pharmacies [Apoteksbolaget]. Swedish drug statistics 1985; 1986; 1987; 1988; 1989; 1990 [Svensk läkemedelsstatistik 1985; 1986; 1987; 1988; 1989; 1990]. Stockholm; Apoteksbolaget, 1986; 1987; 1988; 1989; 1990; 1991. In Swedish.
7. The National Corporation of Swedish Pharmacies [Apoteksbolaget]. Swedish drug statistics 91; 92; 93; 94; 95; 96 [Svensk läkemedelsstatistik 91; 92; 93; 94; 95; 96]. Stockholm: Apoteksbolaget, 1992; 1993; 1994; 1995; 1996; 1997. In Swedish.
8. The National Board of Health and Welfare [Socialstyrelsen]. Classification of diseases 1987 [Klassifikation av sjukdomar 1987]. Stockholm: Socialstyrelsen, 1986. In Swedish.
9. The Federation of County Councils [Landstingsförbundet]. Costs per patient in inpatient care 1993 [Kostnader per intagen patient 1993]. Stockholm: Landstingsförbundet, 1995. In Swedish.
10. Läkemedelsstatistik AB. Medical Index Sweden (MIS). Statistical survey of prescriptions and diagnoses in Sweden. Stockholm: Läkemedelsstatistik AB, 1986, 1988, 1991, 1996.
11. The Federation of County Councils [Landstingsförbundet]. Statistical yearbook for county councils 1997 [Statistisk årsbok för landsting 1997]. Stockholm: Landstingsförbundet, 1996. In Swedish.
12. Statistics Sweden. Statistical yearbook of Sweden 1997 [Statistisk årsbok 1997]. Stockholm: Statistics Sweden, 1997.
13. Ballatori E, Roila F, Berto P, et al. Cost and cost effectiveness analysis of ondansetron versus metoclopramide regimens. A hospital perspective from Italy. PharmacoEconomics 1994; 5: 227-37.
14. Cunningham D, Gore M, Davidson N, Miocevich M, Manchanda M, Wells N. The real costs of emesis - An economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer 1993; 29A: 303-6.
15. Tanneberger S, Lelli G, Martoni A, Piana E, Pannuti F. The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index). J Chemother 1992; 4: 326-31.
16. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994; 51: 1555-63.
17. Plosker GL, Milne RJ. Ondansetron. A pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. PharmacoEconomics 1992; 2: 285-304.
18. Plosker GL, Benfield P. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting. PharmacoEconomics 1996; 9: 357-74.
19. Börjeson S. Nausea and emesis in cancer chemotherapy: aspects of occurrence, assessment and treatment [dissertation]. Stockholm: Karolinska Institute, 1998.
20. Dranisaris G. Using filgrastim efficiently. PharmacoEconomics 1996; 9: 466-8.
21. Frampton JE, Faulds D. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. PharmacoEconomics 1996; 9: 76-96.
22. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stemcell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-7.
23. Stahel RA, Jost LM, Honegger H, Betts E, Goebel MEM, Nagler A. Randomized trial showing equivalent efficacy of filgrastim 5 μg/kg/d and 10 μg/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997; 15: 1730-5.
24. Ragnarson Tennvall G, Fernberg J-O. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage HIB and IV non-small cell lung cancer. Med Oncol. In press.
25. Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997; 8: 525-9.
26. Covens A, Boucher S, Roche K, et al. Is paclitaxel and cisplatin a cost effective first-line therapy for advanced ovarian carcinoma? Cancer 1996; 77: 2086-91.
27. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15: 632-9.
28. Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. Cancer 1996; 78: 2366-73.
29. McGuire W, Neugut AI, Arikian S, Doyle J, Dezii CM. Analysis of the cost effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15: 640-5.
30. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 1996; 334: 1-6.
31. Varenhorst E, Carlsson P, Pedersen K. Clinical and economic considerations in the treatment of prostate cancer. PharmacoEconomics 1994; 6: 127-41.
32. Henriksson F, Hjortsberg C, Rehnberg C, Ödegaard K. Pharmaceuticals and health care costs [Läkemedlen och sjukvårdskostnaderna - Några utvecklingslinjer]. IHE Working Paper 1997: 6. Lund: IHE, 1997. In Swedish.